番茄社区app

More favorable-risk patient population may explain variance from other recent studies

Results "signal a paradigm shift," expert says

Other studies look at financial toxicity for teen/young adult cancer patients, nausea after chemo

Poorer survival outcomes plus more toxicity versus rucaparib alone

Also in TTHealthWatch: diabetes in kids after COVID

Risk was highest in women with deep infiltrating endometriosis and/or ovarian endometriomas

Clear cell histology "is what yields the super response we see in these trials," expert suggests

PFS was not significantly different for those who skipped lymphadenectomy

Incidence, mortality double over 20 years, while estrogen plus MPA lowers endometrial cancer risk

The drug had favorable safety compared with first-generation PARP inhibitors in phase I/II study

Study shows it may be an alternative to cancer-specific mortality for some cancers, but not all

About half of patients responded, duration of response as long as 19 months in three trials

And what abdominal surgery could mean in the context of cancer

News, features, and commentary about cancer-related issues